<DOC>
	<DOCNO>NCT02531568</DOCNO>
	<brief_summary>The purpose study evaluate effect MT-3995 PK warfarin</brief_summary>
	<brief_title>Drug Interaction Study Warfarin MT-3995</brief_title>
	<detailed_description>The purpose study evaluate potential effect multiple daily dose MT-3995 PK ( S ) -warfarin ( R ) -warfarin single-dose administration racemic warfarin</detailed_description>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Able willing provide write informed consent participate study Healthy , free clinically significant illness disease White Caucasian male female , age 18 55 year Body weight range 50 ( female ) 60 ( male ) to110 kg ( inclusive ) Must coagulation test result ( include international normalised ratio [ INR ] activate partial thromboplastin time [ aPTT ] ) within laboratory reference range Screening . Presence history serious adverse reaction allergy medicinal product Known contraindication adverse reaction warfarin . Presence Cytochrome P450 2C9 ( CYP2C9 ) Vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) genetic polymorphism know increase warfarin sensitivity Screening . Known contraindication heparin administration . Known contraindication parenteral vitamin K administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>